(Press-News.org) DURHAM, N.C. -- Duke Medicine researchers have identified biochemical changes in people taking antidepressants – but only in those whose depression improves. These changes occur in a neurotransmitter pathway that is connected to the pineal gland, the part of the endocrine system that controls the sleep cycle, suggesting an added link between sleep, depression and treatment outcomes.
The study, published on July 17, 2013, in the journal PLOS ONE, uses an emerging science called pharmacometabolomics to measure and map hundreds of chemicals in the blood in order to define the mechanisms underlying disease and to develop new treatment strategies based on a patient's metabolic profile.
"Metabolomics is teaching us about the differences in metabolic profiles of patients who respond to medication, and those who do not," said Rima Kaddurah-Daouk, PhD, associate professor of psychiatry and behavioral sciences at Duke Medicine and leader of the Pharmacometabolomics Research Network.
"This could help us to better target the right therapies for patients suffering from depression who can benefit from treatment with certain antidepressants, and identify, early on, patients who are resistant to treatment and should be placed on different therapies."
Major depressive disorder – a form of depression characterized by a severely depressed mood that persists two weeks or more – is one of the most prevalent mental disorders in the United States, affecting 6.7% of the adult population in a given year.
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants for major depressive disorder, but only some patients benefit from SSRI treatment. Others may respond to placebo, while some may not find relief from either. This variability in response creates dilemmas for treating physicians where the only choice they have is to test one drug at a time and wait for several weeks to determine if a patient is going to respond to the specific SSRI.
Recent studies by the Duke team have used metabolomics tools to map biochemical pathways implicated in depression and have begun to distinguish which patients respond to treatment with an SSRI or placebo based on their metabolic profiles. These studies have pointed to several metabolites on the tryptophan metabolic pathway as potential contributing factors to whether patients respond to antidepressants.
Tryptophan is metabolized in different ways. One pathway leads to serotonin and subsequently to melatonin and an array of melatonin-like chemicals called methoxyindoles produced in the pineal gland. In the current study, the researchers analyzed levels of metabolites within branches of the tryptophan pathway and correlated changes with treatment outcomes.
Seventy-five patients with major depressive disorder were randomized to take sertraline (Zoloft) or placebo in the double-blind trial. After one week and four weeks of taking the SSRI or placebo, the researchers measured improvement in symptoms of depression to determine response to treatment, and blood samples were taken and analyzed using a metabolomics platform build to measure neurotransmitters.
The researchers observed that 60 percent of patients taking the SSRI responded to the treatment, and 50 percent of those taking placebo also responded. Several metabolic changes in the tryptophan pathway leading to melatonin and methoxyindoles were seen in patients taking the SSRI who responded to the treatment; these changes were not found in those who did not respond to the antidepressant.
The results suggest that serotonin metabolism in the pineal gland may play a role in the underlying cause of depression and its treatment outcomes, based on the biochemical changes that were seen to be associated with improvements in depression.
"This study revealed that the pineal gland is involved in mechanisms of recovery from a depressed state," said Kaddurah-Daouk. "We have started to map serotonin which is believed to be implicated in depression, but now realize that it may not be serotonin itself that is important in depression recovery. It could be metabolites of serotonin that are produced in the pineal gland that are implicated in sleep cycles.
"Shifting utilization of tryptophan metabolism from kynurenine to production of melatonin and other methoxyindoles seems important for treatment response but some patients do not have this regulation mechanism. We can now start to think about ways to correct this."
The identification of a metabolic signature for patients who have a milder form of depression and who can improve with use of placebo is critically important for streamlining clinical trials with antidepressants. The Duke team is the first to start to define in depth early biochemical effects of treatment with SSRI and placebo, and a molecular basis for why antidepressants take several weeks to start showing benefit.
In future studies, researchers may collect blood samples from patients during both the day and night to define how the circadian cycle, changes in sleep patterns, neurotransmitters and hormonal systems are modified in those who respond and do not respond to SSRIs and placebo. This can lead to more effective treatment strategies.
###
In addition to Kaddurah-Daouk, study authors include Hongjie Zhu, Stephen H. Boyle and Erik Churchill of Duke; Ranga R. Krishnan of Duke and Duke-NUS Graduate Medical School in Singapore; John A. Rush of Duke-NUS Graduate Medical School in Singapore; Mikhail B. Bogdanov of Weill Cornell Medical College in New York; Wayne Matson and Swati Sharma of Bedford VA Medical Center in Massachusetts; Samantha Matson of Bedford VA Medical Center and Massachusetts General Hospital; Oliver Fiehn of the University of California, Davis; Eve Pickering and Marielle Delnomdedieu of Pfizer Global R&D; and additional members of the Pharmacometabolomics Research Network.
Kaddurah-Daouk and several of the study authors hold patents in the metabolomics field. A full list of author disclosures can be found in the manuscript. The research was supported by the National Institute of General Medical Sciences (RC2-GM092729) and Pfizer.
Biochemical mapping helps explain who will respond to antidepressants
2013-07-18
ELSE PRESS RELEASES FROM THIS DATE:
Infection biology: How Legionella subverts to survive
2013-07-18
Bacteria of the genus Legionella have evolved a sophisticated system to replicate in the phagocytic cells of their hosts. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have now identified a novel component of this system.
In humans, Legionella is responsible for the so-called Legionnaires' disease, a form of bacterial pneumonia that is often lethal. The bacteria can also cause Pontiac fever, a flu-like condition characterized by coughing and vomiting. Most Legionella-associated illnesses in humans are caused by Legionella pneumophila.
These microorganisms ...
Avocado farmers face unique foe in fungal-farming beetle
2013-07-18
Beetles with unusual "green thumbs" for growing fungi are threatening avocado crops and could transform into a more destructive pest, according to an international team of researchers.
Ambrosia beetles are insects that bore into trees and cultivate fungi to use as a food source for their young. The fungi -- species of Fusarium -- carried by types of the Ambrosia beetle can damage or even kill trees, making the beetle and its fungi a threat to avocado production in the U.S. and Israel, according to Matthew Kasson, who recently received his doctorate in forest pathology ...
Cancer 'prehabilitation' can reduce complications and improve treatment outcomes
2013-07-18
Philadelphia, Pa. (July 18, 2013) - For patients with cancer, "prehabilitation"— interventions given between the time of diagnosis and the start of treatment—has the potential to reduce complications from treatments and improve physical and mental health outcomes, according to a report in the August American Journal of Physical Medicine & Rehabilitation (AJPM&R). AJPM&R, the official journal of the Association of Academic Physiatrists, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
"A growing body of evidence supports preparing newly diagnosed ...
Stanford scientists break record for thinnest light-absorber
2013-07-18
Stanford University scientists have created the thinnest, most efficient absorber of visible light on record. The nanosize structure, thousands of times thinner than an ordinary sheet of paper, could lower the cost and improve the efficiency of solar cells, according to the scientists. Their results are published in the current online edition of the journal Nano Letters.
"Achieving complete absorption of visible light with a minimal amount of material is highly desirable for many applications, including solar energy conversion to fuel and electricity," said Stacey Bent, ...
Pro athletes can resume careers after cervical spine fusion surgery, reports Neurosurgery
2013-07-18
Philadelphia, Pa. (July 18, 2013) – Most professional athletes are able to return to competition within a year after vertebral fusion surgery on the upper (cervical) spine, reports a study in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Another study in the July Neurosurgery finds variations in treatment for patients with minor head injuries seen in the emergency department (ED) versus the doctor's office. A third paper discusses the ...
Researchers report a complete description of gene expression in the human retina
2013-07-18
BOSTON -- Investigators at Massachusetts Eye and Ear and Harvard Medical School have published the most thorough description of gene expression in the human retina reported to date. In a study published today in the journal BMC Genomics, Drs. Michael Farkas, Eric Pierce and colleagues in the Ocular Genomics Institute (OGI) at Mass. Eye and Ear reported a complete catalog of the genes expressed in the retina.
The retina is the neural tissue in the back of the eye that initiates vision. It is responsible to receiving light signals, converting them into neurologic signals ...
Research leads to successful restoration of hearing and balance
2013-07-18
MANHATTAN, Kan. -- The sounds of success are ringing at Kansas State University through a research project that has potential to treat human deafness and loss of balance.
Philine Wangemann, university distinguished professor of anatomy and physiology in the College of Veterinary Medicine, and her international team have published the results of their study in the July issue of the journal PLOS Genetics: "SLC26A4Targeted to the Endolymphatic Sac Rescues Hearing and Balance in SLC26A4 Mutant Mice."
"When the SLC26A4 gene is mutated, it leads to a loss of pendrin expression, ...
Evolutionary changes could aid fisheries
2013-07-18
Evolutionary changes induced by fisheries may benefit the fishers, according to a new study published last week in the Proceedings of the National Academy of Sciences. But if fisheries are not well-managed, this potential benefit turns into economic losses, as stocks decline from overfishing and further suffer from evolution.
The bad news is that today very few fisheries are managed in a way that will lead to yield increases in the long term. While these fisheries may not be in danger of collapsing, IIASA Evolution and Ecology Program Leader Ulf Dieckmann says, "There ...
New approach to protecting prion protein from altering shape
2013-07-18
A team of researchers from Case Western Reserve University School of Medicine have identified a mechanism that can prevent the normal prion protein from changing its molecular shape into the abnormal form responsible for neurodegenerative diseases. This finding, published in the July 18 issue of Cell Reports, offers new hope in the battle against a foe that until now has always proved fatal.
Prion diseases include Creuzfeldt-Jakob disease and fatal familial insomnia. Unlike other transmissible diseases, the infectious agent is not a virus or bacteria, but an abnormally ...
Scientists develop new way to measure cumulative effect of head hits in football
2013-07-18
WINSTON-SALEM, N.C., July 18, 2013 -- Scientists at Wake Forest Baptist Medical Center have developed a new way to measure the cumulative effect of impacts to the head incurred by football players.
The metric, called Risk Weighted Cumulative Exposure (RWE), can capture players' exposure to the risk of concussion over the course of a football season by measuring the frequency and magnitude of all impacts, said senior author of the study Joel Stitzel, Ph.D., chair of biomedical engineering at Wake Forest Baptist and associate head of the Virginia Tech-Wake Forest University ...